These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10898275)

  • 1. Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with R-hirudin.
    Schenk JF; Berg G; Mörsdorf S; Stefan B; Kroll H; Krischek B; Pindur G; Schieffer H; Wenzel E
    Clin Appl Thromb Hemost; 2000 Jul; 6(3):151-6. PubMed ID: 10898275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Anguenot T; Bernard Y; Bassand JP
    Am J Hematol; 1995 Sep; 50(1):20-5. PubMed ID: 7668220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
    Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
    Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
    Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B
    Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
    Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).
    Olbrich K; Wiersbitzky M; Wacke W; Eichler P; Zinke H; Schwock M; Möx B; Kraatz G; Motz W; Greinacher A
    Blood Coagul Fibrinolysis; 1998 Apr; 9(3):273-7. PubMed ID: 9663711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia.
    Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T
    Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
    J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin-induced thrombocytopenia and thrombosis. Thrombosis as an early cardinal symptom of heparin allergy].
    Folwaczny EK; Stürmer KM
    Chirurg; 2002 Dec; 73(12):1197-203. PubMed ID: 12491049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hirudin-based anticoagulant strategy during isolated limb perfusion in a patient with heparin-induced thrombocytopenia.
    Lindemann W; Richter S; Schilling MK
    Melanoma Res; 2005 Aug; 15(4):287-90. PubMed ID: 16034307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study.
    Huhle G; Hoffmann U; Hoffmann I; Liebe V; Harenberg JF; Heene DL
    Thromb Res; 2000 Aug; 99(4):325-34. PubMed ID: 10963783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
    Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
    J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of heparin-induced thrombocytopenia.
    Keeling D; Davidson S; Watson H;
    Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
    Huhle G; Geberth M; Hoffmann U; Heene DL; Harenberg J
    Gynecol Obstet Invest; 2000; 49(1):67-9. PubMed ID: 10629377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
    Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
    Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
    Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
    Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anticoagulant therapy with recombinant hirudin in patients with thrombopenia induced by heparin].
    Schiele F; Vuillemenot A; Mouhat T; Kieffer Y; Anguenot T; Bernard Y; Bassand JP
    Presse Med; 1996 May 4-11; 25(16):757-60. PubMed ID: 8692751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.